We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
- Authors
Jaiswal, Bijay S; Janakiraman, Vasantharajan; Kljavin, Noelyn M; Eastham-Anderson, Jeffrey; Cupp, James E; Liang, Yuxin; Davis, David P; Hoeflich, Klaus P; Seshagiri, Somasekar
- Abstract
Oncogenic RAS is a highly validated cancer target. Attempts at targeting RAS directly have so far not succeeded in the clinic. Understanding downstream RAS-effectors that mediate oncogenesis in a RAS mutant setting will help tailor treatments that use RAS-effector inhibitors either alone or in combination to target RAS-driven tumors.
- Publication
PloS one, 2009, Vol 4, Issue 5, pe5717
- ISSN
1932-6203
- Publication type
Journal Article
- DOI
10.1371/journal.pone.0005717